In recent developments, HC Wainwright & Co. has updated its price target for Dyne Therapeutics (DYN, Financial). The prominent analyst, Andrew Fein, has maintained a "Buy" rating on the stock, indicating ongoing confidence in its future prospects.
However, the price target for DYN has been adjusted from a previous value of $46.00 to a new target of $38.00. This adjustment represents a 17.39% decrease from the prior price target. The evaluation comes amidst a comprehensive analysis of the company's current market performance.
The revised target and maintained rating were officially reported on May 9, 2025. Despite the lowered target, HC Wainwright & Co.'s position continues to advocate for DYN as a viable investment, retaining the "Buy" status in their latest advisory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Dyne Therapeutics Inc (DYN, Financial) is $49.77 with a high estimate of $66.00 and a low estimate of $30.00. The average target implies an upside of 340.63% from the current price of $11.30. More detailed estimate data can be found on the Dyne Therapeutics Inc (DYN) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Dyne Therapeutics Inc's (DYN, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.